A novel nomogram containing acute radiation esophagitis predicting radiation pneumonitis in thoracic cancer receiving radiotherapy
Authors:
Open Access
- 22 May 2021
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-11
Abstract
Background: Radiation-induced pneumonitis (RP) is a non-negligible and sometimes life-threatening complication among patients with thoracic radiation. We initially aimed to ascertain the predictive value of acute radiation-induced esophagitis (SARE, grade ≥ 2) to symptomatic RP (SRP, grade ≥ 2) among thoracic cancer patients receiving radiotherapy. Based on that, we established a novel nomogram model to provide individualized risk assessment for SRP. Methods: Thoracic cancer patients who were treated with thoracic radiation from Jan 2018 to Jan 2019 in Shandong Cancer Hospital and Institute were enrolled prospectively. All patients were followed up during and after radiotherapy (RT) to observe the development of esophagitis as well as pneumonitis. Variables were analyzed by univariate and multivariate analysis using the logistic regression model, and a nomogram model was established to predict SRP by “R” version 3.6.0. Results: A total of 123 patients were enrolled (64 esophageal cancer, 57 lung cancer and 2 mediastinal cancer) in this study prospectively. RP grades of 0, 1, 2, 3, 4 and 5 occurred in 29, 57, 31, 0, 3 and 3 patients, respectively. SRP appeared in 37 patients (30.1%). In univariate analysis, SARE was shown to be a significant predictive factor for SRP (P < 0.001), with the sensitivity 91.9% and the negative predictive value 93.5%. The incidence of SRP in different grades of ARE were as follows: Grade 0–1: 6.5%; Grade 2: 36.9%; Grade 3: 80.0%; Grade 4: 100%. Besides that, the dosimetric factors considering total lung mean dose, total lung V5, V20, ipsilateral lung mean dose, ipsilateral lung V5, and mean esophagus dose were correlated with SRP (all P < 0.05) by univariate analysis. The incidence of SRP was significantly higher in patients whose symptoms of RP appeared early. SARE, mean esophagus dose and ipsilateral mean lung dose were still significant in multivariate analysis, and they were included to build a predictive nomogram model for SRP. Conclusions: As an early index that can reflect the tissue’s radiosensitivity visually, SARE can be used as a predictor for SRP in patients receiving thoracic radiation. And the nomogram containing SARE may be fully applied in future’s clinical work.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (No. 81502667)
- Key Research and Development Plan of Shandong, China (No. 2016GSF201167)
- Natural Science Foundation of Shandong Province (2019PH111)
This publication has 29 references indexed in Scilit:
- Dosiomics: Extracting 3D Spatial Features From Dose Distribution to Predict Incidence of Radiation PneumonitisFrontiers in Oncology, 2019
- Radiation Pneumonitis after Intensity-Modulated Radiotherapy for Esophageal Cancer: Institutional Data and a Systematic ReviewScientific Reports, 2019
- Predictors of Acute Radiation Esophagitis in Non-small Cell Lung Cancer Patients Treated With Accelerated Hyperfractionated ChemoradiotherapyAnticancer Research, 2018
- Prediction of Radiation Esophagitis in Non–Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine LevelsTranslational Oncology, 2018
- Radiation PneumonitisClinics in Chest Medicine, 2017
- Radiation EsophagitisArchives of Pathology & Laboratory Medicine, 2015
- Effect of Normal Lung Definition on Lung Dosimetry and Lung Toxicity Prediction in Radiation Therapy Treatment PlanningInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlatesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Randomized phase III trial of radiation treatment ± amifostine in patients with advanced-stage lung cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001